Rapid attenuation of anti–SARS–CoV‐2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after COVID‐19: comment on the article by Curtis et al
暂无分享,去创建一个
S. Higa | A. Ogata | S. Kawada | K. Kawamoto | A. Kumanogoh | Y. Kato | Naoko Fujii | T. Morita | M. Okamoto | Kazuki Matsukawa | Y. Yamaguchi | H. Shimagami | N. Ishikawa | Yutaka Ishida
[1] S. Aoki,et al. Castleman disease and TAFRO syndrome , 2022, Annals of Hematology.
[2] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 , 2021, Arthritis & rheumatology.
[3] J. Izopet,et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.
[4] D. Segev,et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series , 2021, Annals of Internal Medicine.
[5] M. Netea,et al. Immune memory in individuals with COVID-19 , 2021, Nature Cell Biology.
[6] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[7] S. Letovsky,et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States , 2021, EClinicalMedicine.
[8] M. Neurath,et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[9] P. Hoff,et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort , 2021, Annals of the Rheumatic Diseases.
[10] Mike Clarke,et al. A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.